Close Menu

NEW YORK (GenomeWeb) – Luminex announced today that it has agreed to acquire MilliporeSigma's flow cytometry portfolio for $75 million, consisting of about $69.9 million to be paid under a stock and asset purchase agreement and about $5.1 million in committed inventory purchases.

Austin, Texas-based Luminex anticipates that the deal will close by the end of 2018 and could contribute between $40 million and $50 million to its revenues in 2019.  

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

New analyses indicate the P.1 variant found in Brazil may be able to infect people who have already had COVID-19, the New York Times reports.

According to CNBC, Novavax's CEO says its vaccine could be authorized in the US as early as May.

The US National Institutes of Health has a new initiative to address structural racism in biomedical research.

In PNAS this week: GWAS of TLV-1-associated myelopathy/tropical spastic paraparesis, analysis of twins with hypertrophic cardiomyopathy, and more.